Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

= .0002) as adverse factors. Over the past decade, utilization and survival after allogeneic transplant have increased in patients ≥70 years. Select adults ≥70 years with hematologic malignancies should be considered for transplant.